Does Hydrocortisone Treatment in Preterm Infants Impact Neurodevelopment?
Because dexamethasone has been associated with long term neurodevelopmental issues when used in very preterm infants, Baud et al. (JAMA, 2017) sought to determine if using hydrocortisone rather than dexamethasone to prevent bronchopulmonary dysplasia was a safe replacement with respect to neurodevelopmental harms. This study was a secondary analysis on a previous study (PREMILOC) that assessed whether hydrocortisone could be used to improve survival in very preterm infants in the setting of bronchopulmonary dysplasia prevention.
Secondary Analysis of a Randomized Controlled Trial (RCT)
To assess the impact of hydrocortisone on neurodevelopment in very preterm infants, 523 infants were given either hydrocortisone (n=256) or a placebo (n=267). Hydrocortisone treatment included 0.5 mg/kg twice a day for seven days, followed by 0.5 mg/kg per day for three days. 406 of the infants survived to age two, and 379 were evaluated (194 in the treatment group and 185 in the control) using a standardized neurological examination and the revised Brunet-Lézine scale. 73% of the treatment group and 70% of the control group had no neurodevelopmental impairment. Mild neurodevelopmental impairment was seen in 20% of the hydrocortisone group and 18% of the placebo group. 7% of the treatment group and 11% of the placebo group had moderate to severe neurodevelopmental impairment. These results were not statistically significant between the groups. Average global development quotient score was not statistically significant between the groups (91.7 in the treatment group and 91.4 in the control group). Rates of cerebral palsy and other major neurological impairments were not significantly different between the groups. The authors conclude that these data indicate that treatment with hydrocortisone does not impact neurodevelopment at two years of age. The authors also suggest for RCTs to make a more definitive assessment of the effects of hydrocortisone on neurodevelopment in extremely preterm infants.
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan